A pilot study of oxidative pathways in MS fatigue: randomized trial of N-acetyl cysteine.
Kristen M KryskoAntje BischofBardia NourbakhshRoland G HenryNisha RevirajanMichael ManguinaoKhang NguyenAmit AkulaYan LiEmmanuelle WaubantPublished in: Annals of clinical and translational neurology (2021)
NAC was well-tolerated in progressive MS, although reduction in fatigue on NAC was similar to placebo. Antioxidant blood and MRS biomarkers were not significantly altered by NAC, which could be due to dose, route of administration, time of sample collection, short half-life, or lack of effect. REGISTERED: clinicaltrials.gov NCT02804594.